lipid nanoparticle — Blog — Markman Advisors

Patent Valuation, Monetization and Investments

Posts tagged lipid nanoparticle

Why did Acuitas bring a patent lawsuit against Arbutus?

The LNP patent battle lines are being drawn. In the past several weeks, Arbutus has sued Moderna, Alnylam has suedboth Moderna and Pfizer, and in the latest, Acuitas Therapeutics has sued Arbutus and Genevant. What can we expect from the Acuitas lawsuit?

Markman AdvisorsApril 1, 2022Arbutus, Arbutus Biopharma, Genevant, Roivant, Moderna, Pfizer, BioNTech, LNP, lipid, lipid nanoparticle, cationic lipid, lawsuit, patent, license, IPR, royalty, Acuitas, Acuitas Therapeutics, Alnylam, Zachary Silbersher, Silbersher, ABUS, MRNA, PFE Comment

What is Alnylam’s Covid patent lawsuit against Moderna and Pfizer all about?

Moderna faces a new patent lawsuit related to its Covid vaccine. On March 17, Alnylam Pharmaceuticals commenced two separate patent lawsuits—one against Moderna and another against Pfizer. Both suits claim that the Covid manufacturers’ vaccines are infringing a patent owned by Alnylam. So what are Alnylam’s lawsuits all about?

Markman AdvisorsMarch 22, 2022Alnylam, Alnylam Pharmaceuticals, Moderna, Moderna Therapeutics, Pfizer, $MRNA, mRNA, $PFE, PFE, MRNA, Arbutus, $ABUS, ABUS, ALNY, $ALNY, vaccine, patent, LNP, lipid, lipid nanoparticle, cationic lipid, nucleic acid, ALC-0315, SM-102, Zachary Silbersher, Silbersher, ONPATTROComment

Can Moderna beat Arbutus’ patent lawsuit for its LNP patents?

Arbutus has finally sued Moderna for allegedly infringing its LNP patents. I previously blogged about the Arbutus/Moderna patent dispute here, here and here. Arbutus has already defended the validity of two of its patents, which puts it case on strong footing. But Moderna may nevertheless have a targeted non-infringement defense that could neutralize Arbutus’ claim to any royalties on Moderna’s Covid vaccine.